Mammary adenocarcinoma

Active Ingredient: Melphalan

Indication for Melphalan

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

High-dose of melphalan used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of mammary adenocarcinoma.

For this indication, competent medicine agencies globally authorize below treatments:

0.15 mg/kg bodyweight or 6 mg/m² body surface area/day for 5 days repeated every 6 weeks

For:

Dosage regimens

Regimen A

Oral, 0.15 milligrams melphalan per kilogram of body weight, once daily, over the duration of 5 days.

Regimen B

Oral, 6 milligrams melphalan per square meter of body surface, once daily, over the duration of 5 days.

Detailed description

Melphalan has been given orally at a dose of 0.15 mg/kg bodyweight or 6 mg/m² body surface area/day for 5 days and repeated every 6 weeks. The dose was decreased if bone marrow toxicity was observed.

100-200 mg/m² body surface area once

For:

Dosage regimens

Intravenous, between 100 milligrams melphalan per square meter of body surface and 200 milligrams melphalan per square meter of body surface, one dose.

Detailed description

Multiple myeloma at a high-dose

The dose regimen is as follows: one dose between 100 and 200 mg/m² body surface area (approximatively 2.5 to 5.0 mg/kg body weight). The dose can be divided equally over 2 or 3 consecutive days. Autologous hematopoietic stem cell transplantation is required following doses above 140 mg/m² body surface area.

It is recommended to ensure patients' adequate hydration and forced diuresis and the prophylactic administration of anti-infective agents (bacterial fungal, viral).

Cyclophosphamide pre-treatment appears to reduce the severity of gastrointestinal damage induced by high-dose.

Adoption of prohylactic measures such as the administration of anti-infective agents can be useful.

The occurrence of GvHD can be prevented by using immunosuppressive therapy after haematopoietic stem cell transplantation as prophylaxis.

Dosage considerations

Melphalan is for intravenous use only.

Risk of extravasation could be observed when melphalan is administered via peripheral intravenous route.

In case of extravasation, the administration should be interrupted immediately and a central venous line route should be used.

Active ingredient

Melphalan

Melphalan is a bifunctional alkylating agent. Formation of carbonium intermediates from each of the two bis-2-chloroethyl groups enables alkylation through covalent binding with the 7-nitrogen of guanine on DNA, cross-linking the two DNA strands and thereby preventing cell replication.

Read more about Melphalan

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.